Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biologic drug
|
| gptkbp:activeDuring |
belimumab
|
| gptkbp:administrativeDivision |
once a month after initial loading doses
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
generic version
|
| gptkbp:brand |
gptkb:Benlysta
|
| gptkbp:clinicalTrials |
gptkb:BLISS-52
gptkb:BLISS-76 Phase III autoimmune disease BLISS-NEO |
| gptkbp:contraindication |
increased risk of infections
hypersensitivity to belimumab |
| gptkbp:developedBy |
gptkb:Human_Genome_Sciences
|
| gptkbp:diseaseResistance |
available
|
| gptkbp:dosageForm |
injection
|
| gptkbp:drugInterdiction |
monoclonal antibody
half-life of approximately 19 days inhibits B-cell survival live vaccines contraindicated other immunosuppressants caution |
| gptkbp:formulation |
lyophilized powder
|
| gptkbp:hasPopulation |
adults
children over 5 years |
| gptkbp:healthcare |
importance of adherence
recognizing signs of infection reporting mood changes |
| https://www.w3.org/2000/01/rdf-schema#label |
Benlysta
|
| gptkbp:is_monitored_by |
mental health
renal function infusion reactions |
| gptkbp:issuedBy |
intravenous infusion
|
| gptkbp:label |
black box warning for serious infections
|
| gptkbp:lastProduced |
2011
|
| gptkbp:mandates |
active lupus nephritis
cutaneous lupus erythematosus lupus arthritis |
| gptkbp:marketedAs |
gptkb:GlaxoSmithKline
|
| gptkbp:offers |
high cost
|
| gptkbp:patentExpiration |
2026
|
| gptkbp:researchFocus |
autoimmune disorders
lupus treatment B-cell biology |
| gptkbp:route |
subcutaneous injection
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
fatigue
headache nausea diarrhea |
| gptkbp:storage |
refrigerated
|
| gptkbp:targets |
B cells
|
| gptkbp:triggerType |
B-lymphocyte_stimulator_(BLyS)_inhibitor
|
| gptkbp:usedFor |
systemic lupus erythematosus
|